RedHill Biopharma announced all enrolled patients completed treatment for the phase II study of its irritable bowel syndrome with diarrhea drug.
Here's what you should know:
1. The company tested a once-daily oral pill of antiemetic drug ondansetron in 127 subjects across 16 U.S. clinical sites.
2. RedHill Biopharma expects to report results of its trial in September 2017.
3. The company believes the treatment has the "potential to be a preferred once-daily treatment" for IBS-D patients.